Journal: Sensors and actuators. B, Chemical

Article Title: Resonant waveguide grating biosensor-enabled label-free and fluorescence detection of cell adhesion

doi: 10.1016/j.snb.2013.08.012

Figure Lengend Snippet: Characterization of the engineered HEK-β2AR-GFP cells. (a-c) Representative fluorescence microscopic images of the engineered cells after overnight culture: (a) epifluorescence image; (b) TIRF image before any treatment; (c) TIRF image after treatment with 1μM isoproterenol for 1hr. For (a-c) the image scale bar is 50 μm. (d-f) The DMR dose responses of isoproterenol in cells after overnight culturing to form monolayer: (d) the parental HEK293 cells; (e) the engineered cells; (f) comparison of the dose-dependent responses of isoproterenol in both types of cells, wherein for the parental cells the DMR amplitude at 50min post stimulation was plotted as a function of isoproterenol dose, and for the engineered cells the DMR amplitudes at both 5min and 50min post stimulation were plotted. For (d-f), the data represents mean±s.d. (n =4).

Article Snippet: Briefly, HEK293 cells were transfected with human pCMV-β 2 AR-GFP plasmid (OriGene Technologies, Inc., Rockville, MD, USA) using Lipofectamine™ LTX and Plus Reagent (Invitrogen) in a 6-well cell culture plate.

Techniques: Fluorescence

Journal: Sensors and actuators. B, Chemical

Article Title: Resonant waveguide grating biosensor-enabled label-free and fluorescence detection of cell adhesion

doi: 10.1016/j.snb.2013.08.012

Figure Lengend Snippet: DMR characterization of HEK-β2AR-GFP cell adhesion. (a, b) The DMR of the engineered cells adherent onto different surfaces under ambient condition: (a) real-time; (b) the DMR amplitudes at 5hr after cell seeding. (c,d) The DMR of the engineered cells adherent onto different surfaces under physiological condition: (c) real-time; (d) the DMR amplitudes at 4hr after cell seeding. The medium only was used as the negative control. For all, the total number of cells added were the same (18,000 cells per well). The data represents mean±s.d. (n =12).

Article Snippet: Briefly, HEK293 cells were transfected with human pCMV-β 2 AR-GFP plasmid (OriGene Technologies, Inc., Rockville, MD, USA) using Lipofectamine™ LTX and Plus Reagent (Invitrogen) in a 6-well cell culture plate.

Techniques: Negative Control

Journal: Sensors and actuators. B, Chemical

Article Title: Resonant waveguide grating biosensor-enabled label-free and fluorescence detection of cell adhesion

doi: 10.1016/j.snb.2013.08.012

Figure Lengend Snippet: DMR characterization of HEK-β2AR-GFP cell adhesion in the presence of different inhibitors under ambient condition. (a-f) The DMR of the engineered cells adherent onto different sensor surfaces: tissue culture treated (a, b), fibronectin coated (c,d), and collagen IV coated (e,f). (a,c,e) real-time DMR; (b,d,f) the DMR amplitudes at 5hr after cell seeding as a function of inhibitor dose. For all, the total number of cells added were the same; that is, 18,000 cells per well. For (a,c,e), the inhibitor dose was fixed to be 10μM, 10μM, 10μM and 1mM for nocodazole, vinblastine, cytochalasin D, and RGD peptide, respectively. The data represents mean±s.d. (n=12 for a, c, and e; n =4 for b, d, and f).

Article Snippet: Briefly, HEK293 cells were transfected with human pCMV-β 2 AR-GFP plasmid (OriGene Technologies, Inc., Rockville, MD, USA) using Lipofectamine™ LTX and Plus Reagent (Invitrogen) in a 6-well cell culture plate.

Techniques:

Journal: Sensors and actuators. B, Chemical

Article Title: Resonant waveguide grating biosensor-enabled label-free and fluorescence detection of cell adhesion

doi: 10.1016/j.snb.2013.08.012

Figure Lengend Snippet: DMR characterization of HEK-β2AR-GFP cell adhesion in the presence of different inhibitors under physiological condition. (a-f) The DMR of the engineered cells adherent onto different sensor surfaces: tissue culture treated (a, b), fibronectin coated (c,d), and collagen IV coated (e, f). (a, c, e) real-time DMR; (b, d, f) the DMR amplitudes at 4hr after cell seeding as a function of inhibitor dose. For all, the total number of cells added were the same; that is, 18,000 cells per well. For (a, c, e), the inhibitor dose was fixed to be 10μM, 10μM, 10μM and 1mM for nocodazole, vinblastine, cytochalasin D, and RGD peptide, respectively. The data represents mean±s.d. (n=12 for a, c, and e; n =4 for b, d, and f).

Article Snippet: Briefly, HEK293 cells were transfected with human pCMV-β 2 AR-GFP plasmid (OriGene Technologies, Inc., Rockville, MD, USA) using Lipofectamine™ LTX and Plus Reagent (Invitrogen) in a 6-well cell culture plate.

Techniques:

Journal: Sensors and actuators. B, Chemical

Article Title: Resonant waveguide grating biosensor-enabled label-free and fluorescence detection of cell adhesion

doi: 10.1016/j.snb.2013.08.012

Figure Lengend Snippet: TIRF images of HEK-β2AR-GFP cells on the fibronectin coated surface under ambient condition. The images were taken 2hrs after cell adhesion onto the fibronectin-coated biosensor surface in the absence and presence of an inhibitor. (a) no any inhibitor; (b) 10μM cytochalasin D; (c) 1mM RGD peptide. The inhibitors were present throughout the cell adhesion process. Image scale bar: 50 μm.

Article Snippet: Briefly, HEK293 cells were transfected with human pCMV-β 2 AR-GFP plasmid (OriGene Technologies, Inc., Rockville, MD, USA) using Lipofectamine™ LTX and Plus Reagent (Invitrogen) in a 6-well cell culture plate.

Techniques:

Journal: Cancers

Article Title: In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies

doi: 10.3390/cancers15010235

Figure Lengend Snippet: Overview of immunotherapeutic strategies and cell lines used in evaluation of their efficacy.

Article Snippet: Tafasitamab (anti-CD19 mAb) , B-ALL cell lines: SEM, Jurkat, CEM, MOLT-16, Nalm-6 cells , [ ] .

Techniques: Bioprocessing

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: Workflow for CTC capture and PD-L1 analysis

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques:

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: Examples of PD-L1 IHC staining of FFPE sections from NSCLC patients (× 100): a PD-L1(−) negative; b positive control (× 200), c PD-L1(+) positive, < 50% immunoreactive, d PD-L1(+) positive, > 50% immunoreactive

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques: Immunohistochemistry, Positive Control

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: PD-L1 expression levels in ten cancer cell lines and in PD-L1 positive and negative control cells from the BioINK staining kit

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques: Expressing, Negative Control, Staining

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: Example images of PD-L1 positive and negative staining patterns

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques: Negative Staining

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: CTC detection rate and PD-L1% in treatment-naïve NSCLC patients

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques:

Journal: Cancer Immunology, Immunotherapy

Article Title: Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer

doi: 10.1007/s00262-019-02344-6

Figure Lengend Snippet: 2 × 2 Confusion matrix and performance measures

Article Snippet: The PD-L1 positive control cell line and the PD-L1 negative control cell line were obtained from InCellDx, Inc. (IncellDx, Menlo Park, CA, USA).

Techniques: